Cargando…

Effect of sertraline in the treatment and prevention of poststroke depression: A meta-analysis

BACKGROUND: Morbidity of poststroke depression (PSD) remains high worldwide. Additionally, PSD causes multiple sequelae. Although sertraline has been reported to be effective in treating PSD, many studies remain inconsistent. METHODS: PubMed, Embase, Scopus, Cochrane Central Register of Controlled T...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Rongfang, Wang, Peng, Gao, Chenhao, Yang, Jianbo, Chen, Zixiao, Yang, Yaoyao, Jiao, Jiawei, Li, Mengmeng, Fu, Bo, Li, Ling, Zhang, Zhenxiang, Wang, Shiguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310584/
https://www.ncbi.nlm.nih.gov/pubmed/30544429
http://dx.doi.org/10.1097/MD.0000000000013453
_version_ 1783383466732158976
author Feng, Rongfang
Wang, Peng
Gao, Chenhao
Yang, Jianbo
Chen, Zixiao
Yang, Yaoyao
Jiao, Jiawei
Li, Mengmeng
Fu, Bo
Li, Ling
Zhang, Zhenxiang
Wang, Shiguang
author_facet Feng, Rongfang
Wang, Peng
Gao, Chenhao
Yang, Jianbo
Chen, Zixiao
Yang, Yaoyao
Jiao, Jiawei
Li, Mengmeng
Fu, Bo
Li, Ling
Zhang, Zhenxiang
Wang, Shiguang
author_sort Feng, Rongfang
collection PubMed
description BACKGROUND: Morbidity of poststroke depression (PSD) remains high worldwide. Additionally, PSD causes multiple sequelae. Although sertraline has been reported to be effective in treating PSD, many studies remain inconsistent. METHODS: PubMed, Embase, Scopus, Cochrane Central Register of Controlled Trials, Clinical trials. gov, Wan fang Data (Chinese), VIP (Chinese), and CNKI (Chinese) were retrieved from inception to April 2017. Randomized controlled trials (RCTs) and self-controlled trials (SCTs) were recruited, which met the inclusion criteria in our study. The depression rating scores, the incidence of PSD, activities of daily living (ADL), neurological impairment scores, and adverse effects were assessed. RESULTS: Around 11 studies were recruited in our work, including 1258 participants. For trials enrolled, the results were depicted: the reduction of depression rating scores was significant in sertraline groups (WMD −6.38; 95% CI −8.63 to −4.14; P < .00001); the incidence of PSD was significantly lower in sertraline groups (RR 0.48; 95%CI 0.35–0.67; P < .0001); there was obvious improvement of ADL (WMD 11.48; 95% CI 4.18–18.78; P = .002 <0.05) and neurological impairment (WMD −3.44; 95% CI −6.66 to −0.21; P = .04 <0.05); no significant difference between sertraline and control groups in the morbidity of adverse events (RR 0.94; 95% CI 0.83–1.06; P = .33 >0.05). However, in sensitivity analyses, the conclusions of the reduction of depression rating scores and the improvement of ADL were altered. CONCLUSIONS: The study suggests that sertraline has a potentially protective role compared with control groups and demonstrates sertraline is safe. However, the reduction of depression rating scores and the improvement of ADL should be considered carefully.
format Online
Article
Text
id pubmed-6310584
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-63105842019-01-14 Effect of sertraline in the treatment and prevention of poststroke depression: A meta-analysis Feng, Rongfang Wang, Peng Gao, Chenhao Yang, Jianbo Chen, Zixiao Yang, Yaoyao Jiao, Jiawei Li, Mengmeng Fu, Bo Li, Ling Zhang, Zhenxiang Wang, Shiguang Medicine (Baltimore) Research Article BACKGROUND: Morbidity of poststroke depression (PSD) remains high worldwide. Additionally, PSD causes multiple sequelae. Although sertraline has been reported to be effective in treating PSD, many studies remain inconsistent. METHODS: PubMed, Embase, Scopus, Cochrane Central Register of Controlled Trials, Clinical trials. gov, Wan fang Data (Chinese), VIP (Chinese), and CNKI (Chinese) were retrieved from inception to April 2017. Randomized controlled trials (RCTs) and self-controlled trials (SCTs) were recruited, which met the inclusion criteria in our study. The depression rating scores, the incidence of PSD, activities of daily living (ADL), neurological impairment scores, and adverse effects were assessed. RESULTS: Around 11 studies were recruited in our work, including 1258 participants. For trials enrolled, the results were depicted: the reduction of depression rating scores was significant in sertraline groups (WMD −6.38; 95% CI −8.63 to −4.14; P < .00001); the incidence of PSD was significantly lower in sertraline groups (RR 0.48; 95%CI 0.35–0.67; P < .0001); there was obvious improvement of ADL (WMD 11.48; 95% CI 4.18–18.78; P = .002 <0.05) and neurological impairment (WMD −3.44; 95% CI −6.66 to −0.21; P = .04 <0.05); no significant difference between sertraline and control groups in the morbidity of adverse events (RR 0.94; 95% CI 0.83–1.06; P = .33 >0.05). However, in sensitivity analyses, the conclusions of the reduction of depression rating scores and the improvement of ADL were altered. CONCLUSIONS: The study suggests that sertraline has a potentially protective role compared with control groups and demonstrates sertraline is safe. However, the reduction of depression rating scores and the improvement of ADL should be considered carefully. Wolters Kluwer Health 2018-12-10 /pmc/articles/PMC6310584/ /pubmed/30544429 http://dx.doi.org/10.1097/MD.0000000000013453 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Research Article
Feng, Rongfang
Wang, Peng
Gao, Chenhao
Yang, Jianbo
Chen, Zixiao
Yang, Yaoyao
Jiao, Jiawei
Li, Mengmeng
Fu, Bo
Li, Ling
Zhang, Zhenxiang
Wang, Shiguang
Effect of sertraline in the treatment and prevention of poststroke depression: A meta-analysis
title Effect of sertraline in the treatment and prevention of poststroke depression: A meta-analysis
title_full Effect of sertraline in the treatment and prevention of poststroke depression: A meta-analysis
title_fullStr Effect of sertraline in the treatment and prevention of poststroke depression: A meta-analysis
title_full_unstemmed Effect of sertraline in the treatment and prevention of poststroke depression: A meta-analysis
title_short Effect of sertraline in the treatment and prevention of poststroke depression: A meta-analysis
title_sort effect of sertraline in the treatment and prevention of poststroke depression: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310584/
https://www.ncbi.nlm.nih.gov/pubmed/30544429
http://dx.doi.org/10.1097/MD.0000000000013453
work_keys_str_mv AT fengrongfang effectofsertralineinthetreatmentandpreventionofpoststrokedepressionametaanalysis
AT wangpeng effectofsertralineinthetreatmentandpreventionofpoststrokedepressionametaanalysis
AT gaochenhao effectofsertralineinthetreatmentandpreventionofpoststrokedepressionametaanalysis
AT yangjianbo effectofsertralineinthetreatmentandpreventionofpoststrokedepressionametaanalysis
AT chenzixiao effectofsertralineinthetreatmentandpreventionofpoststrokedepressionametaanalysis
AT yangyaoyao effectofsertralineinthetreatmentandpreventionofpoststrokedepressionametaanalysis
AT jiaojiawei effectofsertralineinthetreatmentandpreventionofpoststrokedepressionametaanalysis
AT limengmeng effectofsertralineinthetreatmentandpreventionofpoststrokedepressionametaanalysis
AT fubo effectofsertralineinthetreatmentandpreventionofpoststrokedepressionametaanalysis
AT liling effectofsertralineinthetreatmentandpreventionofpoststrokedepressionametaanalysis
AT zhangzhenxiang effectofsertralineinthetreatmentandpreventionofpoststrokedepressionametaanalysis
AT wangshiguang effectofsertralineinthetreatmentandpreventionofpoststrokedepressionametaanalysis